Press releases

(August 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Peripheral Cutting...

(August 23, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its FilterWire EZ Embolic...

(August 19, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved extending the shelf life of its TAXUS Express2...

(August 10, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has made a significant equity investment in Northstar Neuroscience, Inc., a privately held company located in...

(August 5, 2004)

(July 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for its second quarter ended June 30, 2004. Net sales for the second quarter were $1.460 billion as...

(July 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA) to begin its...

(July 21, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2004 on Monday, July 26, at 9:00...

(July 16, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it is expanding its voluntarily worldwide recall to include certain additional units of its TAXUS™ Express2™...

(July 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that enrollment has begun in its clinical trial known as FLAME. This prospective, multi-center, randomized study will...

(July 2, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it is voluntarily recalling nationwide approximately 200 units of its TAXUS™ Express2™ Paclitaxel-Eluting...

(June 30, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2004 on Monday, July 19, at 9:00...

(June 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today the completion of its public offering of $600 million aggregate principal amount of 5.45 percent Senior Notes due June...

(June 22, 2004) - Boston Scientific Corporation (NYSE: BSX) announced today the launch of a public offering of $500 million aggregate principal amount of senior notes, under the Company's existing...

(June 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in Goldman Sachs' 25th Annual Healthcare Conference, which is being held June 7-10 in Dana Point, CA. Larry...

(June 3, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for the...

and Valencia, California (June 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) and Advanced Bionics Corporation, a privately held company located in Valencia, CA, today announced the...

(May 28, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a decision by the U.S. District Court in Wilmington,...

and Paris (May 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month sub-population data from its TAXUS VI clinical trial. The trial enrolled 448 patients at 44 sites...

and Paris (May 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month results from its TAXUS VI clinical trial. The trial enrolled 448 patients at 44 sites in Europe,...

(May 24, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has completed enrollment in ARRIVE, a peri-approval registry. ARRIVE was designed to collect and analyze...

(May 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast an analyst meeting it is hosting on Wednesday, May 26, in conjunction with the Paris Course on Revascularization (PCR), the...

and New Orleans, LA (May 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced sub-population data from a 12-month, 117-patient study of the Enteryx procedure for patients...

and New Orleans, LA (May 18, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced clinical trial data supporting the safety and effectiveness of the Enteryx procedure in relieving...

(May 17, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Banc of America Securities Health Care Conference 2004, which is being held May 19-21 in Las Vegas....